CASI Pharmaceuticals (CASI) director reports fully vested option stakes
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
CASI Pharmaceuticals, Inc. director Thomas Folinsbee filed a Form 3 detailing his initial beneficial ownership in stock options on the company’s ordinary shares. The options are fully vested and exercisable as of the filing date.
Disclosed positions include options over 11,231 ordinary shares at an exercise price of $1.26 per share expiring on July 21, 2035, and options over 20,000 shares at $3.59 per share expiring on June 26, 2034. Additional fully vested options cover 11,231 shares at $2.67 per share expiring on June 18, 2034, and 11,231 shares at $1.93 per share expiring on April 14, 2033.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Folinsbee Thomas
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 11,231 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option holding at $1.26: 11,231 shares at $1.26
Largest option grant: 20,000 shares at $3.59
Option holding at $2.67: 11,231 shares at $2.67
+1 more
4 metrics
Option holding at $1.26
11,231 shares at $1.26
Fully vested options expiring July 21, 2035
Largest option grant
20,000 shares at $3.59
Fully vested options expiring June 26, 2034
Option holding at $2.67
11,231 shares at $2.67
Fully vested options expiring June 18, 2034
Option holding at $1.93
11,231 shares at $1.93
Fully vested options expiring April 14, 2033
Key Terms
Form 3, Option (right to buy, Ordinary Share, fully vested and exercisable
4 terms
Form 3 regulatory
"filed a Form 3 detailing his initial beneficial ownership"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
Option (right to buy financial
"security title is listed as Option (right to buy) on ordinary shares"
fully vested and exercisable financial
"The options are fully vested and exercisable as of the date of this form"
FAQ
What does CASI (CASI) director Thomas Folinsbee report in his Form 3?
Thomas Folinsbee reports initial beneficial ownership of several stock option grants on CASI ordinary shares. All reported options are fully vested and exercisable, with exercise prices between $1.26 and $3.59 per share and expirations from 2033 through 2035.
What is the largest CASI option position reported by Thomas Folinsbee?
The largest single option position reported covers 20,000 CASI ordinary shares at an exercise price of $3.59 per share. This grant is fully vested and exercisable and is scheduled to expire on June 26, 2034, according to the Form 3 disclosure.
Are Thomas Folinsbee’s CASI stock options already vested?
Yes. A footnote states that all reported options are fully vested and exercisable as of the Form 3 date. This means Folinsbee can exercise each option grant at its stated exercise price any time before the respective expiration date.
What expiration dates apply to the CASI options held by Thomas Folinsbee?
The disclosed CASI options expire on April 14, 2033, June 18, 2034, June 26, 2034, and July 21, 2035. Each grant is fully vested and exercisable, giving multi‑year windows during which the director may choose to exercise the options.